percholesterolemia. To our knowledge, no studies have assessed the effects of EGFR TKIs on serum cholesterol levels in humans. Therefore, we investigated the effects of EGFR TKI gefitinib on serum cholesterol levels in non-small cell lung cancer patients.
Methods

Study participants
Patients with histologically confirmed primary lung cancer between January 2001 and December 2012 were enrolled in this study.
All data were collected retrospectively by a comprehensive review of the patients' medical charts. We divided the patients into two groups (gefitinib treatment and control groups) according to the treatment they received. A total of 299 patients who underwent gefitinib treatment for at least 1 month were included in the gefitinib treatment group. Patients who took gefitinib for less than 1 month, who received mixed therapy consisting of gefitinib and other anticancer drugs, or who were prescribed medications known to influence serum lipid levels (e.g., angiotensin II receptor blockers or statins) were excluded from the study. A total of 72 patients who underwent other forms of treatment (e.g., operative treatment, chemotherapy, or radiotherapy)
were included in the control group to evaluate changes in lipid profiles following alternate cancer therapy. Informed consent was obtained from all patients after the nature of the procedure had been fully explained. This study was approved by the Institutional Review Board of Chungnam National University Hospital (Daejeon, Korea).
Clinical and laboratory profiles
Information on patient age, sex, body mass index (kg/m 2 ), cancer stage at diagnosis, pathology reports, and laboratory profiles were collected through medical chart reviews. Blood chemistry and lipid profiles were measured using a blood chemistry analyzer (Hitachi 747; Tokyo, Japan). Gefitinib was administered orally at a dose of 250 mg/day. We analyzed laboratory and clinical parameters before and 1 month after gefitinib treatment to investigate the efficacy of gefitinib. EGFR genotyping was performed using a PNAClamp TM EGFR Mutation Detection kit (Panagene, Inc., Daejeon, Korea).
Statistical analyses
Statistical analyses were performed using SPSS version 18.0 statistical software (SPSS Inc., Chicago, IL, USA). Differences in the baseline characteristics of the two groups were analyzed using independent sample t-tests or a one-way analysis of variance. A paired t-test was used to compare the means of the measured variables. The association between EGFR mutations and the variables evaluated was assessed using analysis of covariance and linear regression analysis with Bonferroni corrections. Results are expressed as means ± SEM.
In all analyses, P< 0.05 was used to indicate statistical significance.
Results
Patient characteristics
The characteristics of the 371 enrolled participants who were diagnosed with primary lung cancer are presented in Table 2 . There were no statistically significant differences in any baseline parameters between the two groups.
Effects of gefitinib treatment on clinical and laboratory parameters
We investigated changes in several parameters in 299 patients before and 1 month after treatment with gefitinib. There were no statis-tically significant changes in weight or body mass index in the gefitinib treatment group (Table 3) . Further, in the gefitinib treatment group, the total cholesterol level decreased from 178.9 to 164.4 mg/dL (P = 0.000), and the triglyceride level decreased from 134.4 to 126.7 mg/dL (P = 0.056) (Fig. 1A) . No significant differences were detected in the control group.
To evaluate the general nutritional status of the patients, protein and leukocyte levels were compared; no statistically significant differences were observed. Creatinine levels increased (P = 0.012), while potassium levels decreased (P = 0.045); however, the changes remained within the normal range and were not clinically significant (Table 3) . Among the 72 patients who underwent some other treatment for primary lung cancer, there were no significant differences in any of the parameters evaluated, including the lipid profile (Table 4) .
Effects of gefitinib treatment on various parameters according to EGFR mutation status
We compared patients with and without EGFR mutations to evaluate the effect of EGFR mutations on serum lipid levels; however, there were no significant differences in body weight or serum levels of hemoglobin, protein, sodium, or potassium between the two groups (Table 5) .
Interestingly, patients with activating EGFR mutations exhibited a 21.3 mg/dL decrease in total cholesterol from the baseline value after 1 month of treatment with gefitinib. Patients with EGFR mutations showed a decrease in total cholesterol from 178± 43 to 152 ± 37 (P< 0.001), but there was no significant difference in patients without EGFR mutations (P = 0.623; Fig. 1B) . Additionally, we analyzed changes in triglyceride levels in relation to EGFR mutation, but there was no significant change between the groups (Fig. 1C) . Also, we an- the EGFR mutation in the gefitinib treatment and control groups. In the gefitinib treatment group, the change of cholesterol was significant in patients with the EGFR mutation (P = 0.003; Table 5 ), but there was no differences in the control group (Table 6 ).
Discussion
In this study, we investigated the potential role of EGFR TKI gefitinib in the treatment of hypercholesterolemia. We found that serum cholesterol levels decreased by 8.1% from baseline levels after treatment with gefitinib for 1 month in patients with non-small cell lung cancer. Moreover, the cholesterol-lowering effects were more significant in lung cancer patients who had activating EGFR mutations.
EGFR TKIs were initially reported as a treatment option for cancer. [13] [14] [15] Recently, several studies have reported that the drug also affects nutrient metabolism. When patients with a malignancy and type 2 diabetes were treated with TKIs, both conditions improved. 16 However, no previous studies have assessed the cholesterol-lowering effects of TKIs. To the best of our knowledge, this is the first report demonstrating statistically significant changes in serum cholesterol levels following gefitinib treatment.
There are several mechanisms by which gefitinib could decrease serum cholesterol levels. First, EGFR TKIs exert anti-inflammatory effects. In high-fat diet fed mice, EGFR TKI treatment improved insulin resistance by decreasing proinflammatory components. 8 For example, erlotinib inhibits TNF-α secretion by suppressing activated T cells. 17 Second, gefitinib might alter bile acid synthesis. In mice in which EGFR was activated by deletion of the Mig-6 gene, we reported that hypercholesterolemia occurred via the downregulation of major enzymes related to bile acid synthesis. 7 We also observed that serum cholesterol levels were decreased by gefitinib treatment in these mice. 18 Interestingly, in our current study, serum cholesterol levels were decreased more in patients with EGFR activating mutations than in those without EGFR mutations. These data support the aforementioned results obtained in gefitinib-treated Mig-6 knockout mice. 7 However, additional studies are needed to validate and evaluate the exact mechanism underlying these effects.
Statins, cholesterol absorption inhibitors, nicotinic acid, and bile acid sequestrants are currently used to lower serum cholesterol. 2 These drugs have been used for several decades, but their preventive effects on cardiovascular-related events are disappointing. 3 Statins decrease serum cholesterol levels from 17 to 31% of baseline levels. 19 In the current study, serum cholesterol was decreased by 8.1% of baseline levels in non-small cell lung cancer patients treated with gefitinib. In patients with EGFR activating mutations, serum cholesterol levels were decreased by 11.5% of baseline levels. The potency of the cholesterol-lowering effect was lower after treatment with gefitinib compared with statins. Nevertheless, statin therapy has some limitations in terms of a limited preventive effect on cardiovascular events, the attainment of target cholesterol levels, and adverse effects. 3, 5 We hypothesize that gefitinib could be used as an additive or alternative therapy in these cases. In particular, these combined or alternative treatments could be more effective in patients with activating EGFR mutations. When we consider that serum cholesterol levels were decreased more in patients with EGFR activating mutations, measuring EGFR signaling might facilitate individualized treatment planning in statin-resistant patients.
There are limitations to our current study. First, all of our subjects were cancer patients. The effects of gefitinib might be affected by the presence versus absence of cancer in patients. Second, lifestyle factors that influence serum cholesterol levels, particularly cholesterol intake and serum levels of each cholesterol fraction, were not monitored in this retrospective study. Third, the effect of tumor progression on cholesterol level could not be excluded. Fourth, since this study was retrospective, there were differences in several clinical characteristics between participants such as lung cancer tumor stage and BMI. Lastly, serum level of LDL-C and HDL-C, the important parameter of metabolic syndrome, were not investigated in this study. To overcome these limitations, a large-scale, prospective, randomized controlled clinical trial is needed.
In conclusion, we found that serum cholesterol levels were decreased by gefitinib treatment in patients with non-small cell lung cancer, particularly in patients with EGFR activating mutations.
EGFR TKI gefitinib might be useful as both a classical anticancer drug as well as an alternative or additive therapy for the treatment of hypercholesterolemia.
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